Abstract: A method for providing a coated vehicle transparency, includes the steps of: (a) providing a vehicle transparency having a vision area and a non-vision area; and (b) applying a sound dampening coating composition to at least a portion of the non-vision area of the transparency. The coating composition can an aqueous dispersion of polymeric microparticles prepared from components including: (i) a functional material selected from (a) a nitrile functional material, (b) an amide functional material, and (c) a carbamate functional material; (ii) a polyoxyalkylene acrylate; and (iii) a filler material.

Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.

Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.

Abstract: A water filter for filtering raw water into potable water having a series of media layers in the following order: 1) sand to gravel or coarse silica; 2) zeolite; 3) activated carbon; 4) a second layer of sand to gravel or coarse silica; and 5) a second layer of zeolite is disclosed. Optionally, the filter further has a ceramic media layer, which may have a reactive coating such as calcium hypochloride. Further options include ferruginous latertic clay spheres (FLCS) or iron oxide brick particles, at least one grid, which may be charged, and/or at least one sand arch. The media layers are contained within at least one vessel. A water filtration system and methods for filtering raw water into potable water are also disclosed.

Abstract: Treatment of un-wetted or low moisture activated carbon with a suitable quantity of carbon dioxide provides a material which, on contact with water, controls pH in treatment water. Use of this treated activated carbon in a water treatment system provides water having an essentially neutral pH which is immediately potable thereby eliminating the necessity to drain and dispose of any soak water. The contact pH of the treated carbon remains within the potable pH range for treatment of more than 100 bed volumes. Additionally, the modified carbon may minimize metal leaching from contaminants in the water.

Abstract: A method for making and organizing a sales territory plan includes guiding users through the development of sales goals, strategies, and targeted lists of accounts derived from the quantifiable characteristics. Historical sales data and strategy are reviewed to define a sales record, which is then segmented based upon commonalties and categorized. The segmented record is analyzed by individual sales territory to create a territory dashboard from which trends and relationships are then evaluated. These trends and relationships are further analyzed using a territory strategies analysis for planning sales strategies based on account segments, sales goals, and other relevant criteria, and to establish a tactical sales action plan. A system and computer process implement one or more steps of the method for territory analysis, goal setting, and strategy and tactics development. In order to derive further benefit execution and follow-up steps are also conducted.

Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.

Abstract: A supplemental lens unit is used on or in combination with a pair of eyeglasses. Lens unit comprises a bridge having at least one prong on each of two ends. Two supplemental lenses are connected by holes positioned near a nasal portion thereof through which prongs protrude. At least one magnet is positioned in peripheral cavities drilled into primary and supplemental lenses. Magnets in each supplemental lens and the corresponding primary lens are of opposite polarity such that lenses are magnetically and removably attached. An example of a method of manufacturing the supplemental lens unit is also disclosed.

Abstract: Aluminum hydroxide fibers approximately 2 nanometers in diameter and with surface areas ranging from 200 to 650 m2/g have been found to be highly electropositive. When dispersed in water they are able to attach to and retain electronegative particles. When combined into a composite filter with other fibers or particles they can filter bacteria and nano size particulates such as viruses and colloidal particles at high flux through the filter. Such filters can be used for purification and sterilization of water, biological, medical and pharmaceutical fluids, and as a collector/concentrator for detection and assay of microbes and viruses. The alumina fibers are also capable of filtering sub-micron inorganic and metallic particles to produce ultra pure water. The fibers are suitable as a substrate for growth of cells. Macromolecules such as proteins may be separated from each other based on their electronegative charges.

Abstract: A computer-assisted method for hierarchically pricing chargeable items in a healthcare provider's chargeable item database is disclosed. The method applies hierarchical pricing to related chargeable items. A system for hierarchically pricing related chargeable items is also disclosed.

Abstract: A case for holding elongate objects, in particular, a case for holding drills or other elongate tools, comprising a housing shell with a lid hinged pivotably to the rear part thereof via a horizontal pivoting axis, wherein a closure device is disposed on the pivotable frontal part of the lid between the lid and the housing shell, wherein the closure device comprises a slide closure with at least one removable safety nub disposed in its slide path.

Abstract: A zero-clearance packaging for elongate objects, in particular, elongate objects subject to fracture, comprises a packaging sleeve with internal and external parts with a closure disposed therebetween which makes it possible to push the parts together in telescope fashion and to hold the same in particular closed position, wherein at least one elastic tension structure is disposed in at least one of the parts, which stricture prestresses the parts in a closure direction of the packaging against the object stored in the packaging. The elastic tension structure comprises bellows formed by an axial pail of the wall of the parts.

Abstract: A level assembly includes a housing having a level mounted within. The housing includes a first arm and a second arm slidably attached to the housing. The first and second arms are both stored in storage positions. Fastener locators associated with each arm are both stored in storage positions. During use the fastener locators are pivoted to an extended position.

Abstract: An apparatus for treating fluids with UV comprises a housing for receiving a flow of fluid having a fluid inlet, a fluid outlet, a reaction chamber; and an assembly of UV sources positioned substantially perpendicular to the fluid. The assembly includes at least first and second pairs of UV sources located in the reactor chamber. The first pair of UV sources has upper and lower UV sources that are positioned relative to each other at a span that is greater than the span between the upper and lower UV sources in the second pair. The second pair is positioned in either the upstream or downstream flow of fluid such that the plane created by the upper UV sources of each pair of UV sources intersects with the plane created by the lower UV sources of each pair of UV sources Subsequent UV sources or pairs of UV sources may be advantageously used. The apparatus may be combined with a baffle arrangement wherein the baffles are preferably positioned in such a way to direct the fluid now into the treatment area.